TiGenix and Fidia Advanced Biopolymers (FAB), both active in the field of tissue engineering and regenerative medicine, have announced that they will join forces for the development and commercialisation of novel biological implants for the repair of damaged and osteoarthritic joints.
ChondroCelect is a characterised cell therapy product for the treatment of symptomatic cartilage defects in the knee. The product has completed a randomised Phase III clinical study.Results from this trial were revealed at the American Academy of Orthopaedic Surgeons conference in February.
Hyalograft C is a hyaluronan-based biocompatible and biodegradable scaffold that was the first three-dimensional cell culture matrix specifically developed for use in cartilage repair and that is currently a market leader in the field in Europe.
The new product will combine TiGenix potent and characterised cells that have the potential to restore stable hyaline-like cartilage with FAB’s easy handling scaffold that can be applied through arthroscopic surgery.
